drugset / Trial / NCT02417142
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
Phase 4
Completed
70 enrolled
University of Massachusetts, Worcester
Stanley Medical Research Institute · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a 24-week, randomized, double-blind, placebo-controlled trial of exenatide weekly injection (2mg per dose) as an adjunctive therapy in 70 schizophrenia subjects to examine exenatide's effects on negative symptoms and cognition.
Timeline
- Start
- 2014-09
- Primary completion
- 2019-07
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exenatide | Peptide | 2 mg | Subcutaneous |